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detecting chikungunya and dengue viral antibodies was 
negative for both infections. In accordance with World 
Health Organization travel guidelines, a blood sample, 
taken 3 days after symptoms onset, was tested at the Na-
tional Institute of Virology (Pune, India) for Ebola virus 
disease. This test used RT-PCR and real-time RT-PCR to 
detect Ebola virus nucleoprotein and polymerase genes 
and ruled out Ebola virus disease.
These tests were repeated with standard positive and 
negative controls to ensure no contamination and no false-
positive results. RT-PCR for chikungunya and dengue vi-
ruses was performed by using virus gene–specific primers. 
RT-PCR for Japanese encephalitis and West Nile viruses 
also were conducted to rule out these cross-reacting arbo-
viral infections that share common clinical manifestations 
with chikungunya and dengue. The failure of MAC-ELISA 
to detect chikungunya virus– and dengue virus–specific 
IgM was attributed to collection of the blood on day 2 af-
ter symptom onset, and thus the IgM would not have been 
generated to be detected by MAC-ELISA.
Fever similar to those common with malaria and ty-
phoid are often exhibited with any of the arboviral infec-
tions that are endemic to Nigeria (1). Often these fevers are 
misdiagnosed as malarial fevers, and the opportunity to test 
for arboviral infections is missed. Dual infections of chi-
kungunya and dengue are becoming more common in India 
(2,3), and there were earlier reports of dengue and malaria 
co-infection (4). Because these diseases are endemic to 
both Nigeria and India and because the incubation periods 
of infections vary, we do not know the exact location where 
the patient acquired any or all of these infections. Multiple 
infections in a single patient would drastically change the 
spectrum of clinical manifestations and thus complicate the 
diagnosis process. Our study particularly draws attention 
to understanding emerging arboviral infections and empha-
sizes the need for a multidimensional diagnostic approach 
in such clinical situations.
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To the Editor: Chikungunya is a dengue-like mosqui-
toborne viral disease that has caused outbreaks in Africa, 
Asia, and the Pacific Islands (1). St. Martin reported the 
first documented occurrence of autochthonous transmis-
sion of chikungunya in the Caribbean islands in December 
2013 (2). Dominica reported its first case on January 17, 
2014 (3). This report describes the outbreak of chikungu-
nya in Dominica through July 12, 2014.
Cases were characterized by using guidelines issued 
by the Centers for Disease Control and Prevention (CDC) 
and the Pan American Health Organization (4). Surveil-
lance of chikungunya cases began on January 16, 2014, 
and data were collected on patients’ age, sex, residence, 
date of illness onset, clinical features, and travel history.
The virus was detected at the Caribbean Public Health 
Agency (CARPHA) laboratory in Trinidad by using a 
real-time PCR (rPCR) developed by CDC; some testing 
was also done at CDC’s Arboviral Diseases Branch in 
Fort Collins, Colorado, USA, by using an IgM ELISA and 
a plaque-reduction neutralization test, as appropriate. All 
suspected infections were laboratory confirmed through 
April 30, 2014, when community transmission was es-
tablished. Thereafter, testing was done only for patients 
hospitalized >48 hours, women in their third trimester of 
pregnancy, patients who died, or patients thought to be in-
fected and coming from geographic areas where chikun-
gunya transmission was not yet established.
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During December 15, 2013–July 12, 2014, a total of 
3,559 chikungunya cases were reported in Dominica, of 
which 141 were confirmed by laboratory testing (134 [95%] 
by rPCR, 7 [5%] by serologic methods). The remaining 
3,418 patients were considered infected (Figure), indicat-
ing an overall attack rate of 5% (on the basis of Dominica’s 
census population for 2011, 71,293). Retrospective inves-
tigation showed that the 2 index patients experienced onset 
of illness during the week beginning December 15, 2013, 
and 1 of the patients had recently traveled from St. Martin. 
The 2 patients were unrelated and resided far apart.
Of the 141 confirmed patients, 78 (55%) were female 
and 60 (43%) were male; data on sex was unavailable for 
3 patients. Mean age of the patients was 34 years (range 13 
days–87 years; median 30 years). Thirty (21%) of the pa-
tients were children <9 years of age; 76 (55%) were 19–49 
years of age. Most patients experienced fever (95%) and 
arthralgia (72%), and 21% of patients experienced rash. No 
deaths associated with chikungunya infection in Dominica 
were reported during the study period.
Across all age groups, more patients were female than 
male, as reported in previous outbreaks (5,6). This trend 
may suggest that, compared with men and boys, women 
and girls have greater health-seeking behaviors, greater 
levels of skin exposure, and potentially greater exposure 
due to peridomestic activities (7).
In this study, a disproportionate number of patients 
were <9 years of age, unlike findings for chikungunya out-
breaks in Indonesia and Réunion Island, where children 
<9 years of age were least affected (7). Of all confirmed 
patients, 55% were 19–49 years of age, suggesting that the 
outbreak had economic effects because workplace produc-
tivity may substantially decrease if disease sequelae (e.g., 
arthralgia and arthritis) cause those affected to take time 
off from work.
Genotypic sequencing identified the Asian genotype of 
chikungunya as the strain currently circulating in the Carib-
bean (8,9). The East/Central/South African genotype was re-
sponsible for the Réunion Island outbreak, and an overall at-
tack rate of 35% was reported after retrospective and active 
case detection (6). Differences in transmission and pathoge-
nicity between genotypes require further investigation.
In response to the Dominica outbreak, a risk commu-
nication plan was developed and implemented on January 
17, 2014, and consisted of 2 phases: an onset emergency 
phase and a control phase. Both phases targeted audiences 
through audio, print, and social media. To control and re-
duce the mosquito population in and around the homes of 
chikungunya patients, vector control activities (i.e., source 
reduction, application of larvicides, and fogging) were in-
tensified with assistance from CARPHA and  Yale Univer-
sity, New Haven, CT, USA. In addition, CARPHA and the 
Pan American Health Organization arranged for delivery 
of insecticide-treated bed nets for use in hospitals and other 
health care settings.
Although the introduction of chikungunya into the 
Caribbean islands may have been anticipated because of 
the broad distribution of the Aedes aegypti mosquito vec-
tor and suitable climatic conditions, our findings show 
that this outbreak could not be prevented. The continuing 
geographic spread of the disease emphasizes the ongoing 
challenge posed by mosquitoborne viral infections result-
ing from globalization and indicates a need for innovative 
prevention and control strategies.
Acknowledgments
We thank the staff of the Princess Margaret Hospital Pathol-
ogy Laboratory, the National Public Health Surveillance and 
Response Team in Dominica, and the CARPHA Laboratory team 










  1. Soumahoro MK, Fontenille D, Turbelin C, Pelat C, Boyd A,  
Flahault A, et al. Imported chikungunya virus infection. Emerg  
Infect Dis. 2010;16:162–3. http://dx.doi.org/10.3201/eid1601.080776
  2. Institut De Veille Sanitaire. Alerte chikungunya dans les Antilles. 
2013 Dec. No 2 [cited 2014 Oct 6]. http://www.ars.guadeloupe.
sante.fr/Le-point epidemiologique.173867.0.html 
  3. Caribbean Public Health Agency. Laboratory country report. Port 
of Spain (Trinidad): The Agency; 2014.
  4. Pan American Health Organization, Centers for Disease Control 
and Prevention. Preparedness and response for chikungunya virus 
introduction in the Americas. 2011 [cited 2014 Nov 12].  
http://stacks.cdc.gov/view/cdc/21188
  5. Lam SK, Chua KB, Hooi PS, Rahimah MA, Kumari S,  
Tharmaratnam M, et al. Chikungunya infection: an emerging 
disease in Malaysia. Southeast Asian J Trop Med Public Health. 
2001;32:447–51.
  6. Laras K, Sukri NC, Larasati RP, Bangs MJ, Kosim R, Djauzi XX, 
et al. Tracking the re-emergence of epidemic chikungunya virus 
in Indonesia. Trans R Soc Trop Med Hyg. 2005;99:128–41. http://
dx.doi.org/10.1016/j.trstmh.2004.03.013
  7. Renault P, Solet JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, 
et al. A major epidemic of chikungunya virus infection on Reunion 
Island, France 2005–2006. Am J Trop Med Hyg. 2007;77:727–31.
  8. Lanciotti, RS, Valadere AM. Transcontinental movement of 
Asian genotype chikungunya virus [letter]. Emerg Infect Dis. 
2014;20:1400–2. 
  9. Leparc-Goffart I, Nougairede A, Cassadou S, Prat C,  
de Lamballerie X. Chikungunya in the Americas. Lancet. 
2014;383:514. http://dx.doi.org/10.1016/S0140-6736(14)60185-9
Address for correspondence: R. Paul Ricketts, Ministry of Health and 
Environment, 4th Fl, Government Headquarters, Kennedy Ave, Roseau, 
Dominica; email: rickettsp@dominica.gov.dm
Acute Zika Virus Infection  
after Travel to Malaysian  
Borneo, September 2014
Dennis Tappe,1 Stephan Nachtigall,1  
Annette Kapaun,1 Paul Schnitzler,  










To the Editor: Zika virus (ZIKV), a mosquito-borne 
flavivirus, causes Zika fever, a self-limiting febrile and 
exanthematic arthralgia syndrome closely resembling 
dengue fever. Most often, signs and symptoms are macu-
lopapular rash, fever, arthralgia, myalgia, headache, and 
conjunctivitis; edema, sore throat, cough, and vomiting 
occur less frequently (1). The virus, which was initially 
isolated from a rhesus monkey (Macaca mulatta) in 1947 
in Uganda, has come to attention recently after a large 
outbreak occurred in the western Pacific region, including 
French Polynesia, New Caledonia, Easter Island, and the 
Cook Islands (2). Travel-related imported infections have 
thus been increasingly reported from the western Pacific 
and sporadically also in travelers to other regions of the 
world, including Thailand, Indonesia, and Senegal (2,3). 
ZIKV is transmitted by different Aedes mosquito species, 
and nonhuman primates play a role as reservoirs (1). After 
the beginning of the ZIKV epidemic in late 2013, a 20-fold 
increase of Guillain-Barré syndrome incidence was noted 
in French Polynesia; 1 patient was infected a week before 
neurologic symptoms started (4). We report an acute ZIKV 
infection in a traveler returning from Malaysian Borneo 
who experienced bilateral hearing difficulties during the 
course of illness.
On September 1, 2014, a 45-year-old woman was seen 
in an outpatient clinic in Heidelberg, Germany for fever of 
up to 39°C and maculopapular rash covering her trunk, arms, 
and legs. Fever had started on August 30, which was 6 days 
after she had returned from a 3-week vacation to peninsular 
Malaysia and Sabah, Malaysian Borneo. Laboratory analy-
ses showed a slightly elevated C-reactive protein level of 
5.2 mg/L (reference range <5.0), but liver function test and 
complete blood count results were within reference range. 
During the next 3 days, the fever subsided, but the patient 
experienced a sore throat, bilateral conjunctivitis, and a 
burning sensation of the palms and soles. These symptoms 
were accompanied by swelling of the hands and increasing 
arthralgia of the wrists, palms, and fingers. There was no 
lymphadenopathy. An indirect immunofluorescence assay 
for ZIKV (3) demonstrated an IgM titer of 1:640 and an IgG 
titer of 1:320 (cutoff <1:20) on day 6 of illness (Figure). An 
indirect immunofluorescence assay for dengue virus demon-
strated an IgG titer of 1:80 and no IgM (cutoff <1:20). 
Two days later, the patient experienced sudden bilater-
al dull and metallic hearing; in her left ear, she experienced 
a very short delay between a sound and her perception of 
the sound. Follow-up ZIKV serologic testing on day 11 of 
illness showed a decreased IgM titer of 1:160 and an in-
creased IgG titer of 1:2,560 (Figure). Viral neutralization 
testing (3) of the same sample demonstrated the presence of 
ZIKV-specific neutralizing antibodies. Chikungunya virus 
serology results were negative. An archived serum sam-
ple from day 3 of illness studied by ZIKV serology and a 
ZIKV-specific real-time reverse transcription PCR (3) was 
negative (Figure). Hearing difficulties lasted for 10 days 
and resolved gradually (Figure). 
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